Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study
Tóm tắt
Despite its well-known benefits, chronic corticosteroid therapy causes osteoporotic fractures in approximately 30−50% of patients treated. To prevent the occurrence of these fractures, treatment with oral bisphosphonates is recommended. However, current oral bisphosphonates, which are given either daily or weekly, are associated with stringent, inconvenient dosing guidelines. Less frequent dosing may provide greater acceptability. The objective of this study was to investigate the efficacy and safety of ibandronate, a highly potent nitrogen-containing bisphosphonate, when given by intravenous (i.v.) injection every 3 months in men and women with established corticosteroid-induced osteoporosis (CIO; lumbar spine [L2-L4] bone mineral density [BMD] T-score ≤−2.5). A total of 115 participants were assigned to receive daily calcium supplements (500 mg) plus either ibandronate (2 mg) injections every 3 months or daily oral alfacalcidol (1 μg), for 3 years. Intermittent i.v. ibandronate injections produced significantly greater increases in mean BMD at the lumbar spine (13.3% versus 2.6%, respectively; p<0.001), and femoral neck (5.2% versus 1.9%, respectively; p<0.001) versus daily oral alfacalcidol, after 3 years, relative to baseline. This study was not statistically powered to show a difference between the groups with respect to fracture incidence. Nevertheless, after 36 months, the frequency of patients with new vertebral fractures was significantly lower in the patients receiving ibandronate relative to those taking alfacalcidol (8.6% versus 22.8%, respectively; p=0.043). This is the first time that significant vertebral fracture reduction has been demonstrated with an i.v. bisphosphonate in CIO. Patients treated with i.v. ibandronate injections also experienced less back pain (p<0.001) and less height loss (p=0.001) than those receiving oral alfacalcidol. Both regimens were well tolerated. In conclusion, intermittent i.v. ibandronate injections are efficacious, well-tolerated, and convenient, and promise to offer physicians an important therapeutic advance in the management of osteoporosis.
Tài liệu tham khảo
citation_journal_title=J Clin Pharm Ther; citation_title=Is enough attention being given to the adverse effects of corticosteroid therapy?; citation_author=DM Hougardy, GM Peterson, MD Bleasel; citation_volume=25; citation_publication_date=2000; citation_pages=227−234; citation_id=CR1
citation_journal_title=BMJ; citation_author=null Walsh; citation_volume=313; citation_publication_date=1996; citation_pages=344; citation_id=CR2
citation_journal_title=Am J Med Sci; citation_author=null Adachi; citation_volume=313; citation_publication_date=1997; citation_pages=41; citation_id=CR3
citation_journal_title=N Engl J Med; citation_author=null Adinoff; citation_volume=309; citation_publication_date=1983; citation_pages=265; citation_id=CR4
citation_journal_title=Ann Rheum Dis; citation_author=null Cooper; citation_volume=54; citation_publication_date=1995; citation_pages=49; citation_id=CR5
citation_journal_title=Ann Intern Med; citation_author=null Lukert; citation_volume=112; citation_publication_date=1990; citation_pages=352; citation_id=CR6
citation_journal_title=Eur J Endocrinol; citation_author=null Reid; citation_volume=137; citation_publication_date=1997; citation_pages=209; citation_id=CR7
citation_journal_title=J Bone Miner Res; citation_author=null Sambrook; citation_volume=5; citation_publication_date=1990; citation_pages=1211; citation_id=CR8
citation_journal_title=Ann Rheum Dis; citation_author=null Verstraeten; citation_volume=45; citation_publication_date=1986; citation_pages=852; citation_id=CR9
citation_journal_title=Calcif Tissue Int; citation_author=null Ringe; citation_volume=60; citation_publication_date=1997; citation_pages=124; citation_doi=10.1007/s002239900200; citation_id=CR10
citation_journal_title=Thorax; citation_author=null Luengo; citation_volume=46; citation_publication_date=1991; citation_pages=803; citation_id=CR11
citation_journal_title=Arthritis Rheum; citation_author=null American; citation_volume=44; citation_publication_date=2001; citation_pages=1496; citation_doi=10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5; citation_id=CR12
citation_journal_title=N Engl J Med; citation_author=null Adachi; citation_volume=337; citation_publication_date=1997; citation_pages=382; citation_id=CR13
citation_journal_title=Arthritis Rheum; citation_author=null Cohen; citation_volume=42; citation_publication_date=1999; citation_pages=2309; citation_doi=10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K; citation_id=CR14
citation_journal_title=J Bone Miner Res; citation_author=null Reid; citation_volume=15; citation_publication_date=2000; citation_pages=1006; citation_id=CR15
citation_journal_title=Arthritis Rheum; citation_author=null Adachi; citation_volume=44; citation_publication_date=2001; citation_pages=202; citation_doi=10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W; citation_id=CR16
citation_journal_title=N Engl J Med; citation_author=null Saag; citation_volume=339; citation_publication_date=1998; citation_pages=292; citation_doi=10.1056/NEJM199807303390502; citation_id=CR17
citation_journal_title=Calcif Tissue Int; citation_author=null Wallach; citation_volume=67; citation_publication_date=2000; citation_pages=277; citation_doi=10.1007/s002230001146; citation_id=CR18
citation_journal_title=N Engl J Med; citation_author=null de; citation_volume=35; citation_publication_date=1996; citation_pages=1016; citation_id=CR19
citation_journal_title=Drugs; citation_author=null Sharpe; citation_volume=61; citation_publication_date=2001; citation_pages=999; citation_id=CR20
citation_journal_title=Drug Safety; citation_author=null Adami; citation_volume=14; citation_publication_date=1996; citation_pages=158; citation_id=CR21
citation_journal_title=Drugs; citation_author=null Adami; citation_volume=57; citation_publication_date=1999; citation_pages=109; citation_id=CR22
Roldán EJA, Negri AL, Gador SA (2000) Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis. The ECMO study. J Bone Miner Res 15 [Suppl 1]:SU411
Lombas C, Hakim C, Zanchetta JR (2000) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15 [Suppl 1]:M406
citation_journal_title=Am J Med; citation_author=null Miller; citation_volume=102; citation_publication_date=1997; citation_pages=43; citation_doi=10.1016/S0002-9343(97)00467-1; citation_id=CR25
citation_journal_title=J Gen Intern Med; citation_author=null Colley; citation_volume=8; citation_publication_date=1993; citation_pages=278; citation_id=CR26
citation_journal_title=Drugs Aging; citation_author=null Stewart; citation_volume=4; citation_publication_date=1994; citation_pages=449; citation_id=CR27
citation_journal_title=Chest; citation_author=null Tashkin; citation_volume=107; citation_publication_date=1995; citation_pages=176S; citation_id=CR28
citation_journal_title=J R Coll Gen Pract; citation_author=null Gatley; citation_volume=16; citation_publication_date=1968; citation_pages=39; citation_id=CR29
Huybrechts KF, Ishak KJ, Caro JJ et al (2002) Implications of non-compliance with osteoporosis treatment in actual practice. Osteoporos Int 13 [Suppl 3]:S48 (Abstract P107)
citation_journal_title=Osteoporos Int; citation_author=null Delmas; citation_volume=13; citation_publication_date=2002; citation_pages=S15; citation_doi=10.1007/s198-002-8331-3; citation_id=CR31
citation_journal_title=J Bone Miner Res; citation_author=null Riis; citation_volume=16; citation_publication_date=2001; citation_pages=1871; citation_id=CR32
citation_journal_title=Am J Med; citation_author=null Thiébaud; citation_volume=103; citation_publication_date=1997; citation_pages=298; citation_id=CR33
Adami S, Delmas P, Felsenberg D et al (2002) Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Osteoporos Int 13 [Suppl 1]: S14 (Abstract O36)
citation_journal_title=Rheumatology; citation_title=Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis; citation_author=JD Ringe, A Dorst, H Faber; citation_volume=42; citation_publication_date=2003; citation_pages=743-749; citation_id=CR35
citation_journal_title=Bone; citation_author=null Ravn; citation_volume=19; citation_publication_date=1996; citation_pages=527; citation_doi=10.1016/S8756-3282(96)00229-3; citation_id=CR36
citation_journal_title=Osteoporos Int; citation_author=null Recker; citation_volume=11; citation_publication_date=2000; citation_pages=S209; citation_id=CR37
citation_journal_title=Calcif Tissue Int; citation_author=null Reginster; citation_volume=65; citation_publication_date=1999; citation_pages=328; citation_doi=10.1007/s002239900706; citation_id=CR38
citation_journal_title=Front Horm Res; citation_author=null Ringe; citation_volume=30; citation_publication_date=2002; citation_pages=127; citation_id=CR39